(Press-News.org) AURORA, Colo. (April 4, 2012) - Men experience a marked drop in their testosterone levels when taking a targeted therapy to control a specific type of lung cancer. That's according to a University of Colorado Cancer Center study published in the April issue of Cancer, the official journal of the American Cancer Society.
Investigators at CU Cancer Center looked at the hormone levels in men with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) taking crizotinib, after a 35-year-old man on the drug reported symptoms that are often attributed to low testosterone levels: fatigue and sexual disinterest.
Crizotinib tablets were licensed by the Food and Drug Administration in August 2011, because of its dramatic and long-lasting suppression of ALK positive lung cancer. ALK positive lung cancer was only recently described so very few cancer centers have a lot of experience identifying and treating this subtype of the disease. CU Cancer Center was involved in the initial development of the drug and has treated one of the largest groups of ALK positive patients in the world.
The testosterone study included 19 men with lung cancer taking crizotinib and 19 men with lung cancer receiving other kinds of therapy. Andrew Weickhardt, MD, senior clinical fellow at the CU Cancer Center, and one of the study's co-authors said listening to the specific issues of that one young man, and a growing awareness of the incidence of low testosterone in cancer patients, made investigators look more closely at their patient population.
"While testosterone was low in only about thirty percent of men on other therapies, it was low in one hundred percent of the men who were on crizotinib. And when we started to track it over time, we could clearly see testosterone levels dropping within days of starting on the drug," said Weickhardt.
As men may stay on crizotinib for months, or even years, the effects of low testosterone could be profound.
"Low testosterone can reduce bone density and muscle strength as well decrease sex drive and increase fatigue and depression. There are many factors associated with a cancer diagnosis that can lower testosterone, but the levels in crizotinib-treated patients were so uniformly low and their direct relationship with starting the therapy meant there was no doubt the drug was contributing to it, " said endocrinologist Micol Rothman, MD, co-author of the study. "Fortunately, we can easily test for and treat this condition."
Matt Ellefson, a lung cancer patient from South Dakota who sought out a second opinion from the University of Colorado program, recalls although his cancer was responding to the crizotinib his energy levels seemed very low. Ellefson's physicians quickly confirmed his testosterone was low and prescribed a testosterone replacement gel.
"The testosterone made an incredible difference in my fatigue and endurance. I could actually feel the difference within 48 hours. Within a week, I had more energy throughout the work day, my running times and workouts improved to the point that I have now entered to run a half-marathon later this year," said Ellefson.
"Testing hormone levels and providing testosterone supplements is a simple way to improve the way these men feel," said Weickhardt. "It's not just about sex drive, it's about overall quality of life."
In recent weeks, several studies from the CU Cancer Center have advanced understanding about ALK positive lung cancer. One study published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR), reveals that when ALK positive lung cancer eventually mutates to become resistant to crizotinib it does so in different ways. Either the cancer changes the ALK protein so that the crizotinib is ineffective against it or it develops another type of cancer molecule that makes the cancer less dependent on ALK. If the ALK protein changes, it may be vulnerable to a stronger ALK inhibitor. If it combines with another type of cancer molecule, a combination of drugs may be required.
Another study published in Cancer, shows different these molecular subtypes of non-small cell lung cancer show distinct patterns of spread in the body.
"Every time we make a discovery, whether it's about the biology or the treatment of ALK or any of the many other emerging subtypes of lung cancer, we are a step closer to making lung cancer less of a headline in people's lives, " said Cancer Center investigator D. Ross Camidge, MD, PhD, director of the thoracic oncology clinical program at University of Colorado Hospital (UCH). "With the testosterone story, we can see that knowing your patients as people allows a good doctor to spot patterns and make breakthroughs that can really improve how someone with lung cancer feels on a daily basis."
The CU Cancer Center's Thoracic Oncology Program is world renowned for its pioneering treatment of lung cancer. The program includes a multidisciplinary team of specialists and subspecialists working together to establish the best treatment plan for each patient. Advanced molecular profiling of a patient's tumor, combined with an extensive array of standard and experimental treatments available through clinical trials has lead to major advances in patient outcomes in the last few years. The program's one-year survival rates for advanced lung cancer consistently run twice as high as the national average. The survival rates at five years run four times higher than the national average.
CU Cancer Center is the lead site for the national Lung Cancer Mutation Consortium, the collaboration of 14 of the nation's elite lung cancer programs. The consortium is profiling ten different molecular abnormalities in lung cancer and pairing them with specific experimental treatments over the next few years.
###Please consider supporting the Lung Cancer Colorado Fund. This unique fund is overseen by the physicians and scientists and supports all aspects of the Center's and University of Colorado Hospital's combined fight against lung cancer.
For an appointment with a University of Colorado physician, please call Tiffany Caudill, intake coordinator for the lung cancer program at 720-848-0392 or email tiffany.caudill@uch.edu. To request physician interviews, please call Erika Matich at 303-524-2780 or email erika.matich@ucdenver.edu
.
Clinical insight improves treatment with new lung cancer drug
Lung cancer drug requires monitoring of testosterone levels
2012-04-05
ELSE PRESS RELEASES FROM THIS DATE:
Dino eggs shape Easter eggs, says new study
2012-04-05
An international group of researchers has helped to determine that dinosaurs have shaped the Easter eggs we buy in the high street.
Scientists investigating whether 70 million-year-old fossil eggs found in the Pyrenees were laid by birds, or their dinosaur ancestors, have published their findings in the current issue of the journal Palaeontology.
And researchers from the University of Leicester have extended the study further by comparing Easter egg shapes to those of birds' and dino eggs.
The authors of the Pyrenees research, Nieves Lopez-Martinez of the Universidad ...
Choice 7's Stealth 2.0 E Cigarette Could Save Lives!
2012-04-05
With over 20,000 Stealth 1.0 e cigarette kits already delivered to active duty troops in combat with no LED at the end, so as to not give position away in a combat situation. The Stealth makes life a little safer from snipers and other dangers of war and police actions.
The new Stealth 2.0 battery, announced on the My 7's Blog, comes with a patent pending switch that is as simple as "Tap & Hold", to switch from stealth mode to regular so that you can see your charge information from your batteries. The Stealth battery gives the user the option to have an ...
Superior Restoration Offers Tips for Choosing a Restoration Company
2012-04-05
In 2011, flood damage in the United States caused economic losses of more than $8 billion. In 2010, fires caused more than $11.6 billion in property damage. Each year, floods, fires and other natural disasters combine to create catastrophic financial problems for home and property owners across the country. This expense can be greatly increased if the wrong contractor or restoration specialist is chosen. In some cases, poor restoration can cause irreparable damage to possessions and homes.
Superior Restoration, a San Diego-based water damage, fire and mold remediation ...
Disarming disease-causing bacteria
2012-04-05
Scientists could produce new antibacterial treatments by disarming the molecular pumps bacteria use to bring disease causing molecules in contact with animals and humans.
Research published today in Nature Structure and Molecular Biology showed a protein complex called the Translocation and Assembly Module (TAM), forms a type of molecular pump, allowing bacteria to shuttle key disease causing molecules from inside the bacterial cell where they are made, to the outside surface, priming the bacteria to infect other organisms.
The international research collaboration, ...
Gene mutation identified as contributor to autism spectrum disorders
2012-04-05
There is little argument among experts that autism spectrum disorders (ASD), complex developmental disabilities that vary widely in their severity, are caused by both genetic and environmental factors. Advances in genome sequencing now permit scientists to uncover specific mutations in DNA that are associated with ASD at unprecedented resolution. Such data are vital to understanding the genetic basis of the disorder.
A new study co-authored by UCLA researchers has led to a better understanding of the genetic contribution to autism using this new approach. By comparing ...
To prevent leukemia's dreaded return, go for the stem cells
2012-04-05
Researchers reporting in the April Cell Stem Cell, a Cell Press publication, have found a way to stop leukemia stem cells in their tracks. The advance in mice suggests that a combination approach to therapy might stamp out chronic myeloid leukemia (CML) for good.
That's in contrast to the vast majority of CML patients taking drugs like imatinib (aka Gleevec) today, who often go into remission only to see their cancer return again. It is those lingering leukemia stem cells, which stubbornly resist existing therapies, that fuel the cancer's comeback.
"Imatinib inhibits ...
Tackling dyslexia before kids learn to read
2012-04-05
For children with dyslexia, the trouble begins even before they start reading and for reasons that don't necessarily reflect other language skills. That's according to a report published online on April 5 in Current Biology, a Cell Press publication, that for the first time reveals a causal connection between early problems with visual attention and a later diagnosis of dyslexia.
"Visual attention deficits are surprisingly way more predictive of future reading disorders than are language abilities at the prereading stage," said Andrea Facoetti of the University of Padua ...
Heightened sensitivity to cheap, high-calorie food is linked with obesity
2012-04-05
Obesity is increasing worldwide in adults and children and is currently viewed by many as one of the most serious threats to public health. It is likely that solutions to the obesity pandemic will require changes in public policy and that scientific insight into obesity will be invaluable for guiding those changes. Now, a new review of human brain imaging studies published by Cell Press in the journal Trends in Endocrinology and Metabolism suggests that a major reason for the dramatic increase in obesity may be a heightened sensitivity to heavily advertised and easily accessible ...
Active older adults less likely to experience psychological distress
2012-04-05
In a study examining the relationship between physical activity and physical function, researchers from Australia discovered that older adults who experienced any level of psychological distress were more than four times more likely to experience functional limitation than those who did not. This study is published in the Journal of the American Geriatrics Society.
Led by Gregory Kolt, PhD, of the University of Western Sydney, School of Science and Health, researchers analyzed data from nearly 100,000 Australian men and women, aged 65 and older, who participated in the ...
New stem cell line provides safe, prolific source for disease modeling and transplant studies
2012-04-05
Researchers have generated a new type of human stem cell that can develop into numerous types of specialized cells, including functioning pancreatic beta cells that produce insulin. Called endodermal progenitor (EP) cells, the new cells show two important advantages over embryonic stem cells and induced pluripotent stem cells: they do not form tumors when transplanted into animals, and they can form functional pancreatic beta cells in the laboratory.
"Our cell line offers a powerful new tool for modeling how many human diseases develop," said study leader Paul J. Gadue, ...
LAST 30 PRESS RELEASES:
Study identifies candidates for therapeutic targets in pediatric germ cell tumors
Media alert: The global burden of CVD
Study illuminates contributing factors to blood vessel leakage
What nations around the world can learn from Ukraine
Mixing tree species does not always make forests more drought-resilient
Public confidence in U.S. health agencies slides, fueled by declines among Democrats
“Quantum squeezing” a nanoscale particle for the first time
El Niño spurs extreme daily rain events despite drier monsoons in India
Two studies explore the genomic diversity of deadly mosquito vectors
Zebra finches categorize their vocal calls by meaning
Analysis challenges conventional wisdom about partisan support for US science funding
New model can accurately predict a forest’s future
‘Like talking on the telephone’: Quantum computing engineers get atoms chatting long distance
Genomic evolution of major malaria-transmitting mosquito species uncovered
Overcoming the barriers of hydrogen storage with a low-temperature hydrogen battery
Tuberculosis vulnerability of people with HIV: a viral protein implicated
Partnership with Kenya's Turkana community helps scientists discover genes involved in adaptation to desert living
Decoding the selfish gene, from evolutionary cheaters to disease control
Major review highlights latest evidence on real-time test for blood – clotting in childbirth emergencies
Inspired by bacteria’s defense strategies
Research spotlight: Combination therapy shows promise for overcoming treatment resistance in glioblastoma
University of Houston co-leads $25 million NIH-funded grant to study the delay of nearsightedness in children
NRG Oncology PREDICT-RT study completes patient accrual, tests individualized concurrent therapy and radiation for high-risk prostate cancer
Taking aim at nearsightedness in kids before it’s diagnosed
With no prior training, dogs can infer how similar types of toys work, even when they don’t look alike
Three deadliest risk factors of a common liver disease identified in new study
Dogs can extend word meanings to new objects based on function, not appearance
Palaeontology: South American amber deposit ‘abuzz’ with ancient insects
Oral microbes linked to increased risk of pancreatic cancer
Soccer heading does most damage to brain area critical for cognition
[Press-News.org] Clinical insight improves treatment with new lung cancer drugLung cancer drug requires monitoring of testosterone levels